Durch unsere Mitgliedschaften in nationalen und internationalen Fachverbänden (DEGRO, ESTRO) sowie der regelmäßigen Teilnahme an Kongressen und Weiterbildungsveranstaltungen halten wir uns ständig auf dem neuesten Kenntnisstand.
Ferrari AC, Stone NN, Kurek R et al.: Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment. J Clin Oncol. 2006 Jul 1;24(19):3081-8.
Roddiger SJ, Kolotas C, Filipowicz I et al.: Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer. Strahlenther Onkol. 2006 Jan;182(1):22-9.
Kurek R, Nunez G, Konrad L et al.: Prognostic value of combined „triple“-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients. Clin Cancer Res. 2004 Sep 1;10(17):5808-14.
Martin T, Roddiger SJ, Kurek R et al.: 3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer. Radiother Oncol. 2004 Apr;71(1):35-41.
Kurek R, Ylikoski A, Renneberg H et al.: Quantitative PSA RT-PCR for preoperative staging of prostate cancer. Prostate. 2003 Sep 1;56(4):263-9.
Kurek R, Kalogera-Fountzila A, Muskalla K et al: Usefulness of tumor volumetry as a prognostic factor of survival in head and neck cancer. Strahlenther Onkol. 2003 May;179(5):292-7.
Roddiger SJ, Renneberg H, Martin T et al.: Human kallikrein 2 (hK2) mRNA in peripheral blood of patients with thyroid cancer: a novel molecular marker? J Cancer Res Clin Oncol. 2003 Jan;129(1):29-34. Epub 2003 Feb 12.
Roddiger SJ, Bojunga J, Klee V et al.: Detection of thyroid peroxidase mRNA in peripheral blood of patients with malignant and benign thyroid diseases. J Mol Endocrinol. 2002 Dec;29(3):287-95.